A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Secukinumab to Demonstrate the 16 Week Efficacy and to Assess the Long Term Safety, Tolerability and Efficacy up to 2 Years in Patients With Active Ankylosing Spondylitis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2018

At a glance

  • Drugs Secukinumab (Primary) ; Secukinumab (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms MEASURE 1
  • Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Jun 2018 Results of pooled data from three phase 3 trials (MEASURE 1-3 [NCT01358175, NCT01649375, NCT02008916]) and from post-marketing analyses, were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of pooled data from psoriatic arthritis (FUTURE 1-3 studies, n=1414) and ankylosing spondylitis (MEASURE 1-4 studies, n=1163) exposed to SEC was evaluated at baseline and at Week 12, 16 (AS only), 24 and 52, were presented at the 19th Annual Congress of the European League Against Rheumatism.
    • 16 Jun 2018 Results of retrospective analysis comparing spinal radiographic progression over two years data from this study to historic control from ENRADAS study presented at the 19th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top